ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 800,85
1,47%
DAX
18 518,03
-0,44%
Brent Oil
83,375
-1,14%
Bitcoin
64 416,77
-0,67%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Actualités

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALTH
DateHeureSourceTitreSymboleSociété
05/10/200913h00Business WireAllos Therapeutics Announces U.S. Availability of FOLOTYN™ (pralatrexate injection) for Relapsed or Refractory Peripheral T...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/10/200923h53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/10/200912h36MarketwiredRothmanResearch.com Stock Review for SCG, CA, NE, MKC, COL and ALTHNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/09/200914h45Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
25/09/200913h00Business WireAllos Therapeutics’ FOLOTYN™ First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/09/200922h15Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/09/200900h09Business WireAllos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN™ (pralatrexate) for the Trea...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/09/200912h00Edgar (US Regulatory)Notice of Effectiveness (EFFECT)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/09/200915h05Edgar (US Regulatory)Post-Effective Amendment to Registration Statement (POS AM)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
01/09/200914h00Business WireAllos Therapeutics to Hold Post Advisory Committee Conference CallNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
31/08/200915h31PR Newswire (US)Seven Summits Research Releases Comments on Boeing, Joy Global, Ciena Corporation, TakeTwo Interactive and Allos TherapeuticsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
28/08/200919h27Dow Jones NewsFDA Has Several Issues With Allos Data For FolotynNASDAQ:ALTHAllos Therapeutics Inc.
14/08/200922h16Edgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/08/200916h25Business WireAllos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Ref...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/08/200923h16Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/08/200922h00Business WireAllos Therapeutics Reports Second Quarter 2009 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
23/07/200916h06Business WireAllos Therapeutics Launches Peripheral T-Cell Lymphoma WebsiteNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
22/07/200914h00Business WireAllos Therapeutics to Report Second Quarter 2009 Results on August 4, 2009NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/07/200914h04Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (S-8)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/07/200914h00Edgar (US Regulatory)Securities Registration Statement (simplified form) (S-3)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/07/200914h07MarketwiredBridgewaterEquity.com Free Fundamental Sector & Market Research on OCR, GGC, NWD, MPW, ALTH and NEXMNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
07/07/200914h00Business WireAllos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/06/200914h40PR Newswire (US)InvestorSoup.com Researches Market Movers: Applied Materials, Allscripts-Misys, Allos, ValueVision, BGC Partners and Warren ResoNASDAQ:ALTH
02/06/200912h05Edgar (US Regulatory)Proxy Statement (definitive) (DEF 14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/05/200914h00Business WireAllos Therapeutics Reports Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual MeetingNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
26/05/200914h00Business WireAllos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review StatusNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
15/05/200900h15Business WireAllos Therapeutics Announces Updated Data from Pivotol Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
12/05/200914h00Business WireAllos Therapeutics to Present at the Eighth Annual JMP Securities Research ConferenceNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/05/200922h00Business WireAllos Therapeutics Reports First Quarter 2009 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/04/200914h31Edgar (US Regulatory)Amended Annual Report (10-K/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Showing the most relevant articles for your search:NASDAQ:ALTH

Dernières Valeurs Consultées

NYSE
JPM
JP Morgan Chase
EU
RNO
Renault
EU
BNP
BNP Paribas
NASDAQ
NVDA
NVIDIA
NYSE
MRK
Merck
NASDAQ
AAPL
Apple
EU
BEL20
Bel 20
EU
PX1
CAC 40
FTSE
UKX
FTSE 100
EU
SGO
Cie de SaintGobain
COIN
ETHUSD
Ethereum
EU
PX4
SBF 120
NASDAQ
GOOGL
Alphabet
EU
RI
Pernod Ricard
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés